目的 探究益生菌聯(lián)合美沙拉嗪在治療潰瘍性結(jié)腸炎（UC）中的遠(yuǎn)期療效。方法 選取2016年1月—2017年1月渭南市中心醫(yī)院確診并進(jìn)行治療的96例UC患者，按照隨機(jī)數(shù)字表法將其均分為觀察組和對(duì)照組，每組48例，其中對(duì)照組患者使用美沙拉嗪進(jìn)行治療，觀察組在對(duì)照組基礎(chǔ)上加用益生菌進(jìn)行治療，治療前后測(cè)定兩組血清腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素1β（IL-1β）及C反應(yīng)蛋白（CRP）水平，對(duì)比兩組治療有效率，治療第3、6個(gè)月對(duì)兩組進(jìn)行隨訪，對(duì)比復(fù)發(fā)率，第6個(gè)月測(cè)定兩組血紅蛋白、紅細(xì)胞壓積及白蛋白水平。結(jié)果 兩組治療前TNF-α、IL-1β及CRP水平無(wú)明顯差異，與治療前對(duì)比，治療后兩組TNF-α、IL-1β及CRP水平出現(xiàn)顯著下降（P<0.05），同時(shí)觀察組TNF-α、IL-1β及CRP水平較對(duì)照組低，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組治療有效率為93.75%，對(duì)照組為83.33%，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。3個(gè)月隨訪觀察組復(fù)發(fā)率為2.08%，對(duì)照組為8.33%；6個(gè)月隨訪觀察組復(fù)發(fā)率為6.25%，低于對(duì)照組的18.75%，差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組血紅蛋白、紅細(xì)胞壓積及白蛋白水平顯著升高，而對(duì)照組則無(wú)顯著變化，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 使用益生菌聯(lián)合美沙拉嗪對(duì)UC進(jìn)行治療的方式切實(shí)有效，不僅能夠提高治療有效率，還能夠改變其血清內(nèi)炎癥因子的含量，同時(shí)降低遠(yuǎn)期復(fù)發(fā)率，效果值得肯定，值得進(jìn)行臨床推廣。

Objective To explore the long-term efficacy of probiotics in the treatment of ulcerative colitis (UC).Methods A total of 96 UC patients diagnosed and treated in our hospital from January 2016 to January 2017 were randomly divided into experimental group and control group, with 48 cases in each group. The control group patients The experimental group was treated with probiotics on the basis of the control group. The levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and C-reactive protein CRP levels were compared between the two groups. The third month and the sixth month of treatment were followed up, the relapse rate was compared, and the hemoglobin, hematocrit and albumin level were measured at the sixth month. Results There was no significant difference in the levels of TNF-α, IL-1β and CRP between the two groups before treatment. Compared with those before treatment, the levels of TNF-α, IL- The levels of TNF-α, IL-1β and CRP in the experimental group were significantly lower than those in the control group (P<0.05). The effective rate was 93.75% in the experimental group and 83.33% in the control group, with significant difference (P<0.05). The recurrence rate was 2.08% in the experimental group and 8.33% in the control group at 3 months of follow-up. The recurrence rate in the 6-month follow-up group was 6.25%, which was lower than that in the control group (18.75%, P<0.05). The levels of hemoglobin, hematocrit and albumin in the experimental group were significantly increased, while those in the control group showed no significant difference (P<0.05).Conclusions The probable treatment of UC with probiotics is effective and effective. It can not only improve the therapeutic efficiency, but also change the content of inflammatory cytokines in the serum, and reduce the long-term recurrence rate. The effect is worthy of clinical promotion.